The new sensor — expected to launch in the second half of 2025 — will provide easier diabetes management for eligible users.

BTIG lowered the firm’s price target on DexCom (DXCM) to $107 from $120 and keeps a Buy rating on the shares as part of a broader research note ...

Dexcom has announced that the U.S. Food and Drug Administration has cleared its G7 15 Day Continuous Glucose Monitoring ...

DexCom Inc. closed 51.60% short of its 52-week high of $139.24, which the company achieved on April 25th.

The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required.

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Dexcom (DXCM – Research Report), with a price target of ...

DexCom, Inc. DXCM recently announced the FDA clearance for its 15-day wear G7 Continuous Glucose Monitoring (CGM) system, the ...

If you're using a Dexcom G7 to monitor your blood sugar in real-time, you can now sync it to your Apple Watch for real-time ...

Dexcom has won a clearance from the FDA for its longest-lasting continuous glucose monitor, a 15-day version of its flagship ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day ...

San Diego-based Dexcom submitted its 15-day G7 CGM to the FDA in October 2024. The company says its 15-day G7 also meets ...

DexCom (NasdaqGS:DXCM) experienced an 12% decline over the past week, during which the company transitioned its audit from Ernst & Young to Deloitte & Touche, and appointed Jon Coleman as Chief ...